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One patient received second-line lapatinib plus capecita-
bine. The median duration of anti-HER2 therapy was 20 
months. Patients received a median of 4 lines of anti-HER2 
therapy.  Conclusions: Durable responses were achieved 
with repeated exposure to anti-HER2 therapy. In a selected 
patient population, trastuzumab monotherapy appears to 
be a reasonable first-line treatment option. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Trastuzumab-based treatment is the standard of care 
for patients with human epidermal growth factor recep-
tor 2 (HER2)-positive breast cancer. Trastuzumab has 
been shown to significantly improve outcomes, including 
overall survival, in randomized phase III trials in both 
early and metastatic breast cancer. In HER2-overexpress-
ing metastatic breast cancer (MBC), Slamon et al.  [1] 
demonstrated significantly improved time to disease pro-
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 Abstract 
 Background: Trastuzumab is an established treatment for 
HER2-positive breast cancer (BC). We analyzed Swiss pat-
terns of care in patients with HER2-positive BC after disease 
progression on trastuzumab-containing therapy for meta-
static BC (MBC).  Patients and Methods: A retrospective anal-
ysis was performed in six Swiss BC centers. Patients with 
HER2-positive MBC treated with at least one infusion of 
trastuzumab for advanced disease between January 2006 
and December 2007 were identified. Treatment patterns in 
first and further lines were analyzed.  Results: All of the 72 
identified patients received trastuzumab as their first pallia-
tive anti-HER2 therapy, either as monotherapy (n = 23) or in 
combination with chemotherapy (typically taxane or vinorel-
bine; n = 49). Median time to progression was 8.1, 8.0 and
7.9 months in the monotherapy, trastuzumab-taxane and 
trastuzumab-vinorelbine cohorts, respectively. After pro-
gression on first-line anti-HER2 therapy, trastuzumab was 
continued in 67 of 68 patients who received further therapy. 
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gression (TTP; primary endpoint), response rate and 
overall survival in patients randomized to trastuzumab 
in combination with chemotherapy compared with pa-
tients receiving chemotherapy alone. This observation 
was confirmed in the M77001 trial evaluating docetaxel 
with or without trastuzumab as first-line therapy for 
MBC  [2] . More recently, the TAnDEM (Trastuzumab and 
Anastrozole Directed Against ER-Positive HER2-Posi-
tive Mammary Carcinoma) trial showed that the addi-
tion of trastuzumab to anastrozole in postmenopausal 
women with HER2-positive hormone-receptor-positive 
MBC significantly improved progression-free survival 
(PFS) and the clinical benefit rate  [3] . A phase II study 
showed that trastuzumab is active as monotherapy in
the first-line treatment of HER2-positive MBC, with re-
sponse rates of up to 35% and a median TTP of almost 4 
months  [4] .
 Unfortunately, most patients will eventually experi-
ence disease progression, posing a therapeutic challenge. 
Lapatinib in combination with capecitabine is an ap-
proved option in this setting, based on results from the 
E100151 randomized phase III trial  [5] . Patients previ-
ously treated with an anthracycline, a taxane and trastu-
zumab were randomized to capecitabine either alone or 
in combination with lapatinib. TTP was significantly im-
proved in the combination arm (hazard ratio 0.49, p  ! 
0.001; median 8.4 months vs. 4.4 months with capecita-
bine alone). Another strategy after progression on tras-
tuzumab is to continue with trastuzumab but to switch 
to another chemotherapy regimen. Retrospective data 
suggested that administration of trastuzumab in multiple 
treatment lines is beneficial compared with discontinu-
ing trastuzumab at first progression  [6–14] . These retro-
spective data were subsequently confirmed in a prospec-
tive randomized trial conducted by the German Breast 
Group (GBG26) in which patients with progression on 
trastuzumab-containing therapy received either cap-
ecitabine alone or capecitabine combined with trastu-
zumab beyond disease progression  [15] . Compared with 
capecitabine alone, continuation of trastuzumab was as-
sociated with a higher response rate and significantly im-
proved TTP (primary endpoint; hazard ratio 0.69; me-
dian 8.2 vs. 5.6 months, respectively). Despite these ob-
servations, considerable variation exists in the use of 
trastuzumab both in the first-line setting and after trastu-
zumab failure. The aim of this retrospective cohort anal-
ysis was to describe and understand treatment decision 
algorithms and to document patient outcomes in Swiss 
clinical practice.
 Patients and Methods 
 The main objective of the study was to describe therapeutic 
strategies in Swiss clinical practice in patients with HER2-posi-
tive MBC. Physicians from six Swiss breast cancer centers par-
ticipated in this retrospective cohort analysis. Medical records 
were reviewed to identify all patients with HER2-positive tumors 
(immunohistochemistry, IHC, 3+ or fluorescence in situ hybrid-
ization, FISH, positive) who received treatment in any line be-
tween January 2006 and December 2007, and who experienced 
progression on trastuzumab-containing therapy. From these re-
cords, data on tumor and patient characteristics, HER2 testing 
method, anti-HER2 therapy, chemotherapy, endocrine therapy, 
tumor response, duration of therapy, sites of metastasis, disease 
progression, survival and safety were collected on a case report 
form and entered into a central database. The data were then an-
alyzed primarily using descriptive statistics. Data collection was 
finished in December 2009. Comparisons of TTP and overall sur-
vival according to chemotherapy regimen were performed using 
the Mann-Whitney U test and one- and two-sided Monte Carlo 
tests. Overall survival was calculated from the time of introduc-
tion of first non-adjuvant trastuzumab treatment. The Pearson   2 
test was used to compare metastatic sites between the treatment 
groups.
 The study was approved (if required) by the local ethics com-
mittee at each of the six participating institutions. The study was 
also approved by the Swiss Federal Commission of Professional 
Secrecy in Medical Research.
 Results 
 Patient Population 
 In total, 72 patients were identified for analysis from 
six Swiss breast cancer centers. All had HER2-positive 
(IHC3+ or FISH-positive) MBC and had shown disease 
progression during or following trastuzumab given in the 
metastatic or relapsed setting. The date of the first breast 
cancer diagnosis ranged from 1990 to 2007. The median 
age of patients was 58 years (range 28–81). Two patients 
had received adjuvant trastuzumab. Nineteen patients 
had metastatic (stage IV) disease at first diagnosis. De-
tails of tumor biology and prior therapy are shown in
 table 1 .
 First-Line Treatment 
 The preferred first-line anti-HER2 treatment was 
trastuzumab in combination with chemotherapy (n = 
49), typically vinorelbine (n = 23) or a taxane (n = 22). The 
remaining 23 patients received trastuzumab monothera-
py. No significant difference in patient characteristics 
was detected between the trastuzumab-alone group and 
the combination group ( table  2 ). However, there was a 
trend (p =  0.08) towards a higher proportion of patients 
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with liver metastases in the combination group (59 vs. 
34% in the monotherapy group) that may have influenced 
treatment outcome. TTP data according to first-line 
trastuzumab regimen are shown in  table 3 . Median TTP 
was very similar in both treatment cohorts, irrespective 
of combination partner (no chemotherapy vs. chemo-
therapy; taxane vs. non-taxane).
 Second and Subsequent Treatment Lines 
 After progression on the first line of trastuzumab-
containing therapy, 68 of the 72 patients (94%) received 
further anti-HER2 therapy. This consisted of trastuzu-
mab in all but 1 patient, who received lapatinib in com-
bination with capecitabine. In the majority of cases, sec-
ond-line treatment comprised trastuzumab in combina-
tion with chemotherapy (n = 51, 75%). As in the first-line 
setting, the predominant chemotherapy partners were 
vinorelbine (n = 27) or a taxane (n = 16). Eight patients 
receiving second-line chemotherapy with trastuzumab 
were re-exposed to the same trastuzumab-chemotherapy 
regimen as they had received in the first line (paclitaxel 
in 2 patients, docetaxel in 1 patient, vinorelbine in 5 pa-
tients). There was no detectable difference in TTP during 
second-line therapy between patients receiving the same 
versus another chemotherapy in combination with 
trastuzumab (median 8.6 vs. 7.1 months, respectively;
p =  0.503). However, the patient numbers in these analy-
ses are too small for meaningful comparison. With fur-
ther treatment lines, the use of lapatinib combined with 
capecitabine increased, from 15% in the third-line setting 
to 20% in the sixth line ( fig. 1 ), but it was still selected less 
frequently than trastuzumab-containing regimens. 
 The median total duration of anti-HER2 therapy was 
20 months (range 0.7–60). After progression on first-line 
trastuzumab-containing treatment, patients received a 
median of 4 distinct lines of anti-HER2 therapy (range 
Table 1.  Summary of baseline characteristics (n = 72)
Value
Median age, years 58 (28–81)
Disease status
M1 (primary metastatic) 19 (26)
Hormone receptor status at first diagnosis
Estrogen receptor positive 
Progesterone receptor positive
40 (56)
21 (29)
Prior treatment before trastuzumab
Neoadjuvant chemotherapy
Adjuvant chemotherapy
Anthracycline-based
CMF alone
Other
Adjuvant trastuzumab
Adjuvant endocrine therapy
5 (7)a
29 (40)
22 (31)b
6 (8)
1 (1)
2 (3)
29 (40)
Prior treatment for advanced disease
(non-trastuzumab) 24 (33)
Chemotherapy
Endocrine therapy
14 (19)c
20 (28)
D ata presented as n (%) or median (range). CMF = Cyclophos-
phamide, methotrexate, 5-fluorouracil.
a Anthracycline-based in 4 of 5 patients, without anti-HER2 
therapy in all cases. 
b With taxane in 2 patients; with sequential CMF in 4 patients. 
c Multiple lines in 5 patients.
Table 2. Patient characteristics before first-line therapy
Trastuzumab p
value
mono-
therapy 
with
chemo-
therapy
Median age, years 55 59 –
Number of metastatic sites, % 
1
≤2
26
78
30
69
–
–
Metastatic sites, %
Liver
Lung
Bone
34
34
70
59
31
55
0.08
0.79
0.31
Disease status at inclusion
26
45
Primary meta static, %
Disease-free interval, monthsa
27
43
–
–
V alues of p calculated using Pearson’s 2 test. 
a n = 53, excludes patients presenting with metastatic disease.
Table 3.  Summary of TTP according to first-line regimen
Patients, n Median TTP
months
p value 
Trastuzumab monotherapy 23 8.1
0.88Trastuzumab combined
with chemotherapy 49 8.1
Taxane regimen 22 8.0 0.88Non-taxane regimen 27 7.9
V alues of p calculated with Mann-Whitney U test.
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1–12). With every line of therapy after first administra-
tion of trastuzumab, there was a decrease in the median 
duration of anti-HER2 therapy and, in most cases, TTP 
( table 4 ). There was no apparent correlation between sec-
ond-line TTP and previous use of trastuzumab as mono-
therapy or in combination with chemotherapy (median 
5.1 months with trastuzumab monotherapy vs. 7.1 months 
with trastuzumab combined with chemotherapy; p = 
 0.92). There was, however, a weak non-significant corre-
lation between TTP in the first- and second-line settings.
 Median overall survival in the entire study population 
was 32.3 months. There was no statistically significant 
difference in overall survival between those receiving 
trastuzumab as monotherapy in the first-line setting and 
those receiving trastuzumab in combination with che-
motherapy (median 36.6 vs. 30.0 months, respectively; 
Mann-Whitney U test, p =  0.063).
 Brain Metastases 
 Overall, 31 of the 72 patients (43%) developed brain 
metastases at some point during the study period. Treat-
ments for brain metastases are summarized in  table  5 . 
Median overall survival after diagnosis of brain metasta-
ses was 9.8 months (95% CI 2.8–16.7). Trastuzumab ther-
apy was the predominant treatment immediately after 
diagnosis of brain metastasis (17 of 31 patients, 55%). Lap-
atinib was used in 3 patients (10%) after diagnosis of brain 
metastases and in an additional 8 patients with brain me-
tastases in subsequent lines. In total, 68% of all patients 
with brain metastasis received at least one anti-HER2 
therapy during further lines of therapy.
 Discussion 
 Trastuzumab is considered the standard first-line 
treatment for HER2-positive MBC and is typically ad-
ministered in combination with chemotherapy  [16] . Our 
observational study of clinical practice and treatment 
patterns indicates that in Swiss breast cancer centers, 
trastuzumab was administered as monotherapy (without 
chemotherapy) in one third of patients receiving first-line 
trastuzumab-based treatment for HER2-positive MBC. 
Table 4.  Summary of treatment duration and TTP according to 
line of therapy
T reatment line
1st 2n d 3rd 4th 5th 6th
Median treatment duration of
anti-HER2 therapy, monthsa 7.5 6.0 4.0 3.0 3.0 2.0
Median duration of
chemotherapy, months 3.9 4.0 3.7 3.0 3.0 2.0
Median time to progression
months 8.0 7.0 5.0 3.9 5.0 2.0
a I ncluding maintenance treatment.
Table 5.  Treatments in patients with brain metastases (n = 31)
Patients 
n
Systemic therapy immediately after diagnosis of 
brain metastases
Trastuzumab 17
Lapatiniba 3
Chemotherapy aloneb 3
No systemic therapy 6
Unknown 2
Anti-HER2-based treatment any time after diagnosis of 
brain metastases
Lapatinib and trastuzumab (all sequentially) 8
Trastuzumab alonec 10
Lapatinib alone 3
Neither lapatinib nor trastuzumab 8
Unknown 2
a  1 patient received trastuzumab in a subsequent line.
b 1 patient received lapatinib in a subsequent line.
c Including 2 patients for whom additional (sequential) lapa-
tinib use is unknown.
100
Pa
tie
nt
s 
(%
)
90
80
70
60
50
40
30
20
10
0
1st line
(n = 72)
Lapatinib-based therapy
Trastuzumab + chemotherapy
Endocrine therapy alone
Trastuzumab monotherapy
Trastuzumab + endocrine therapy
Chemotherapy alone
2nd line
(n = 68)
3rd line
(n = 60)
4th line
(n = 48)
5th line
(n = 30)
6th line
(n = 20)
 Fig. 1. Summary of treatment according to line. 
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The median TTP with first-line treatment was 8.1 months, 
both in patients receiving trastuzumab monotherapy and 
those in whom trastuzumab was combined with chemo-
therapy. The strategy of first-line trastuzumab mono-
therapy in selected patients did not appear to negatively 
influence overall survival. In fact, there were no detect-
able differences between the cohorts in age, number of 
metastatic sites before first-line therapy, initial disease 
status, disease-free interval and institution, although 
there was a numerically higher proportion of patients 
with liver metastases in the combination group (59 vs. 
34% in the trastuzumab monotherapy group). This may 
have influenced outcome, and suggests that patients re-
ceiving trastuzumab alone had a better prognosis than 
those in whom trastuzumab combined with chemother-
apy was selected. Consistent with this hypothesis, medi-
an TTP in our trial (8 months) is higher than the 4- to 
5-month median TTP reported in trials of trastuzumab 
monotherapy in the literature  [4] .
 Results from two small randomized trials compar-
ing trastuzumab monotherapy with the combination of 
trastuzumab and chemotherapy as first-line treatment 
contrast in part with our observations. In the HERTAX 
trial (n = 99), PFS was significantly worse with mono-
therapy compared with combination therapy (hazard 
ratio 2.51, p  ! 0.001; median 3.9 vs. 9.4 months, respec-
tively)  [17] . However, when TTP was measured for the 
sequence of trastuzumab followed by chemotherapy, ef-
ficacy was similar (hazard ratio 1.33, p = 0.20; median 
9.9 vs. 9.4 months, respectively). There was no statisti-
cally significant difference in overall survival between 
the two groups. In the second trial (n = 107), conducted 
in Japan, the sequence of trastuzumab monotherapy fol-
lowed by chemotherapy and trastuzumab resulted in 
similar PFS (to second progression in the sequential 
arm) to first-line trastuzumab in combination with che-
motherapy (median 12.4 vs. 14.6 months, respectively) 
 [18] . However, overall survival was significantly supe-
rior for the combination treatment, resulting in prema-
ture termination of the trial. As with our study, there are 
some important caveats when interpreting the results of 
these two trials. In the HERTAX trial, patients starting 
with trastuzumab monotherapy were switched to che-
motherapy at progression and trastuzumab mainte-
nance therapy was not planned. Furthermore, in both 
trials there was no central HER2 testing. Consequently, 
less rigorous patient selection may have led to inappro-
priate use of trastuzumab monotherapy in some pa-
tients. In addition, both trials included relatively small 
numbers of patients.
 In our retrospective cohort study, the proportions of 
patients receiving taxane or vinorelbine chemotherapy
in combination with first-line trastuzumab were similar. 
There was no significant difference in TTP between these 
two regimens. This observation is consistent with results 
of two randomized trials, which showed similar efficacy 
with taxane or vinorelbine chemotherapy in combination 
with trastuzumab in the first-line setting  [19, 20] .
 Despite the proven efficacy of trastuzumab in MBC, 
there is still variation in the approach to anti-HER2 ther-
apy, particularly following disease progression on tras-
tuzumab-containing therapy. The anti-HER2 treatment 
strategy for MBC in Swiss breast cancer centers typically 
involves multiple trastuzumab-containing regimens. 
Our results, which are similar to other retrospective stud-
ies, indicate that durable disease control can be achieved 
with repeated or prolonged exposure to trastuzumab. 
The median TTP of 6 months with second-line treatment 
in our study is consistent with reports in the literature  [21, 
22] . The predominant chemotherapy partners in the sec-
ond-line setting were vinorelbine and taxane, as in the 
first-line setting.
 Although the combination of lapatinib and capecita-
bine was approved in Switzerland in May 2007 after tras-
tuzumab failure, and an early access program was avail-
able in 2007, the regimen was reserved until the third-line 
setting in the majority of patients in our study. Further-
more, even in later lines, the use of trastuzumab-based 
regimens was at least twice as high as that of lapatinib-
based regimens. This finding is surprising when consid-
ering that data from the randomized E100151 trial of lap-
atinib and capecitabine were available during the study 
period, whereas use of trastuzumab beyond progression 
was supported only by retrospective and anecdotal data 
at that time. Data from the randomized GBG26 trial sug-
gesting benefit with trastuzumab beyond progression 
were first presented in December 2007. It is possible that 
some patients in our study were not eligible for lapatinib, 
as the regimen was registered only for treatment after ex-
posure to an anthracycline and a taxane. However, this is 
unlikely to explain why the use of lapatinib was so rare in 
later lines of therapy, where selection of trastuzumab re-
mained more frequent. A more plausible reason for the 
preference for trastuzumab over lapatinib concerns prac-
tical difficulties with the use of lapatinib. Certainly dur-
ing the treatment period analyzed in this study, many 
physicians were more familiar with trastuzumab treat-
ment and were less experienced in the management of 
lapatinib side effects, and thus may have felt less comfort-
able with administering lapatinib than trastuzumab.
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 The proportion of patients with brain metastases in 
our study is in line with previous reports and showed a 
gradual increase with each line of therapy.
 In conclusion, in our observational study, trastuzu-
mab monotherapy was chosen in one third of patients in 
the first-line setting. In this selected patient population, 
trastuzumab monotherapy appeared to be as effective as 
trastuzumab in combination with chemotherapy in terms 
of TTP. However, it remains to be elucidated whether 
these selected patients may have had an even better out-
come if they had received combined first-line immuno-
chemotherapy. The randomized SAKK 22/99 trial has 
been designed to address this question by comparing 
trastuzumab alone vs. trastuzumab in combination with 
chemotherapy as first-line therapy for HER2-positive 
MBC, and its results are eagerly awaited.
 Surprisingly, lapatinib was not used until the third-
line setting; even in later lines, trastuzumab remained the 
preferred approach and only a minority of patients re-
ceived lapatinib. The clinical practice adopted in Switzer-
land between 2006 and 2007, typically involving contin-
ued exposure to anti-HER2 treatment across several lines 
of chemotherapy, provided sustained disease control and 
median overall survival of 32 months.
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